All studies
AuthorisedTherapeutic confirmatory (Phase III)Interventional

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Nalbuphine Extended- Release Tablets for the Treatment of Chronic Cough in Participants with Idiopathic Pulmonary Fibrosis (IPF) (OCEAN-1)

Idiopathic pulmonary fibrosis (IPF) is a condition that causes lung scarring, often leading to a persistent, tiring cough that has few effective treatments. The OCEAN-1 study is a Phase III clinical trial designed to find out whether an extended-release tablet called nalbuphine ER can help ease this symptom. Participants will be randomly assigned to take either nalbuphine ER tablets or a matching dummy pill (placebo) every day for 26 weeks. Neither the participants nor their doctors will know who receives which treatment until the study ends. Researchers will measure how often participants cough over 24-hour periods and ask them to rate how severe their cough feels. The trial aims to see if the medicine safely and noticeably lowers daily coughing compared to placebo, potentially offering a new way to help manage this challenging symptom.

At a glance

Status
Authorised
Phase
Therapeutic confirmatory (Phase III)
Sponsor
Trevi Therapeutics Inc.
Enrolment target
39
Start
28 Oct 2026

What is this study about?

Idiopathic pulmonary fibrosis, often shortened to IPF, is a long-term lung condition where the tissue inside the lungs becomes thick, stiff, and scarred over time. One of the most distressing and exhausting daily symptoms for people with IPF is a persistent, dry cough. Unfortunately, standard cough medicines rarely provide relief, leaving many people feeling worn out and frustrated.

This research study, named OCEAN-1, is exploring whether a tablet called nalbuphine extended-release (ER) can help. Nalbuphine acts on specific receptors in the nervous system to help calm the urge to cough. The 'extended-release' design means the medicine is slowly absorbed into the body throughout the day, providing steady support.

The trial is a Phase III study, which means the drug has already passed early safety checks and is now being tested in a larger group of people to confirm how well it works. By comparing nalbuphine ER against a dummy pill (placebo), doctors hope to prove whether it truly makes a meaningful difference to coughing and everyday quality of life for people with IPF.

Key takeaways

  • Tests whether nalbuphine ER tablets help reduce chronic cough in people with IPF.
  • Open to adults aged 18 and older diagnosed with idiopathic pulmonary fibrosis.
  • Participants take either the real medicine or a dummy pill (placebo) for 26 weeks.
  • Coughing is tracked using a 24-hour monitor and patient questionnaires.
  • Participation is completely voluntary and you can stop at any time.

Who may be eligible?

This trial is open to adults aged 18 and older who have been diagnosed with idiopathic pulmonary fibrosis (IPF) and are troubled by an ongoing, chronic cough. Both men and women are welcome to take part.

To join, participants must be able to attend regular clinic check-ups and agree to follow the study schedule, which includes wearing a special monitor to track coughing.

Because this is a clinical trial, there are certain medical conditions or existing medications that might mean someone cannot take part. Your doctor or the study team will carry out health checks and review your full medical history to confirm whether the trial is safe and suitable for you.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

  1. I am 18 years of age or older.
  2. I have been diagnosed by a doctor with idiopathic pulmonary fibrosis (IPF).
  3. I suffer from a persistent, long-lasting cough.
  4. I am willing to wear a small 24-hour cough monitor at scheduled times.
  5. I can attend regular clinic check-ups over a period of 26 weeks.
Answer every question to see your result.

What does participation involve?

Taking part in the study lasts for at least 26 weeks (about six months). If you join, you will be given study tablets to take by mouth each day. You will have a 50-50 chance of receiving either the active nalbuphine ER medicine or a dummy pill (placebo) that looks identical.

Throughout the study, you will visit the hospital clinic for routine health checks, blood tests, and breathing assessments. At set times, you will be asked to wear a small, lightweight cough recording monitor for 24 hours so doctors can count how many times you cough. You will also fill in simple questionnaires asking how severe your cough feels and how it affects your sleep and daily activities.

Potential risks and benefits

Taking part may help reduce your cough, but there is no guarantee you will personally benefit, especially if you receive the placebo tablet. The information gathered may help improve future care for people with IPF. Like all medicines, nalbuphine ER can cause side effects, which may include tiredness, dizziness, nausea, or headache, though your medical team will monitor you closely at all times. Joining is entirely voluntary, and you are free to leave the trial at any stage without it affecting your standard NHS medical care.

Locations (2)

Some site locations are approximate. We're improving this — please verify with the trial team before travelling.
  • —
    Unverified
    Spain
  • —
    Unverified
    Poland

Common questions

What is a placebo and why is it used?

A placebo is an inactive pill that looks just like the real medicine. Comparing the study drug to a placebo helps researchers prove that any improvement is genuinely caused by the medicine itself.

Will I know if I am taking the real medicine or the dummy pill?

No. This is a 'double-blind' trial, which means neither you nor your study doctor will know which pill you are receiving until the entire study has finished.

How is my cough measured during the study?

You will wear a small, non-invasive digital monitor that listens to and counts your coughs over a full 24-hour period, and you will complete simple cough rating scales.

Do I have to pay to take part in this trial?

No. All study medication, tests, and medical visits related to the trial are provided free of charge, and travel expenses are often reimbursed.

Can I continue taking my regular IPF medications?

In many cases, yes. However, the trial team will need to review all of your current prescription and over-the-counter medicines to make sure they are safe to use alongside the study drug.

How to find out more

Always speak to your GP or specialist before deciding to take part in a study.

Discussion

Community discussion

Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.